The mechanisms of measles virus (MV) vaccine attenuation are insufficiently characterized. Because the Edmonston vaccine strain can enter cells through CD46 in addition to the primary MV receptor signaling lymphocyte activation molecule (SLAM or CD150), we asked whether and how its tropism is altered. In human tonsillar tissue, this vaccine strain infects naive (CD45RA + CD62L + ) T lymphocytes, which express SLAM very infrequently, with much higher efficiency than do wild-type strains. By contrast, it infects B lymphocytes, macrophages, and NK cells with significantly lower efficiencies than those of wild-type strains. Infection levels by wild-type strains correlate with the frequency of SLAM expression and are highest in B cells, which are 40%-55% infected. SLAM-expressing T cells are more readily infected by all MV strains than are SLAMexpressing B cells. Thus, vaccine attenuation may be caused by tropism alteration in combination with suboptimal replication.
, has been used to characterize the mechanisms of interference between MV and HIV infections using a vaccine lineage strain and a wild-type-derived laboratory-passaged Chicago-1 strain [22] .
Here, we used the system to compare the spread of a bona fide MV vaccine strain with that of 3 bona fide wild-type strains. Two of the wild-types were recently isolated in the United States [23] and propagated exclusively on Vero/human signaling lymphocyte activation molecule (hSLAM or CD150) cells [24] . The third was derived from infectious MV cDNA [12] and is amenable to reverse genetics. We also used a virus from an infectious cDNA derived from a vial of the Moraten vaccine strain [25] . Moraten is one of several vaccine strains originating from the clinical isolate Edmonston, differs by 1-6 aa/protein from the lowest available passage stock of this isolate, and is identical to the Schwartz vaccine strain, despite a nominally different origin [26] .
We reasoned that the cellular tropism of the Moraten/Schwartz vaccine strain may differs from that of wild-type strains. These strains use as a receptor SLAM, a T cell activation molecule [27] also expressed in certain B lymphocytes [28] and other activated lymphoid cells [24, 29, 30] . This vaccine strain can also enter cells through the ubiquitous regulator of complement activation CD46 [31] [32] [33] . By comparing the tropism of this vaccine strain with that of wild-type strains, we noticed that it infects less efficiently every cell type that we examined, except for T lymphocytes. Because naive T lymphocytes infrequently express SLAM, we asked whether the vaccine strain infects these cells more efficiently than do the wild-type strains. It did, adding tropism alteration to reduced replication efficiency as a possible cause of immunosuppression.
MATERIALS AND METHODS

Cells and viruses.
All cells were cultured and maintained at 37ЊC in 5% CO 2 in Dulbecco's modified Eagle medium (DMEM) that contained 10% fetal bovine serum. Vero/hSLAM cells (African green monkey kidney cells expressing human SLAM [24] , provided by Dr. Y. Yanagi, Kyushu University, Fukuoka, Japan) were cultured in the presence of 0.5 mg/mL G418, penicillin, and streptomycin. Helper 293-3-46 cells for virus rescue [34] were grown in the presence of 1.2 mg/mL G418. B95a (a marmoset B cell line provided by Dr. D. Gerlier, University of Lyon, Lyon, France) and Vero cells were grown in plain medium.
Wild-type strains MVwtD4 and MVwtD8 (provided by P. Rota, Centers for Disease Control and Prevention, Atlanta, GA; see [23] for review) were propagated on Vero/hSLAM for 3 passages. Both recombinant MVwtICB (provided by Dr. K. Takeuchi, University of Tsukuba, Tsukuba, Japan) [35] and MV vaccine strain (MVvac) [25] were generated from full-length cDNA as described by Radecke et al. [34] . Single syncytia were picked and propagated on Vero/hSLAM cells and amplified.
Virus stock preparation. Virus stocks were prepared from Vero/hSLAM cells infected at an MOI of 0.03 TCID 50 /cell with the relevant virus and incubated at 32ЊC. Cells were scraped in Opti-MEM (Invitrogen), and particles were released by 2 freeze-thaw cycles. Titers were determined by TCID 50 titration on Vero/hSLAM cells according to the Spearman-Kär-ber method [36] .
Receptor usage of vaccine and wild-type strains. B95a ( cells/well), Vero, and Vero/hSLAM ( cells/well) 5 5 5 ϫ 10 2.5 ϫ 10 cells were infected in a 12-well plate with MVvac, MVwtICB, MVwtD4, and MVwtD8 at 0.1 TCID 50 /cell diluted in 0.5 mL of Opti-MEM for 2 h at 37ЊC. Two hours after infection, the Opti-MEM was replaced with DMEM-10% fetal calf serum. Syncytia formation was photographed under phase-contrast microscopy 36 h after infection.
Tissue maintenance and infection. Human tonsils removed during routine tonsillectomies were dissected, set up in culture, and maintained as described elsewhere [21] . For each experimental condition, 54 tissue blocks were used: each 1-2-mm/side cubic block (3.3 mg) contained ∼ cells (i.e., 6 3.5 ϫ 10 lymphocytes). Experiments were repeated using tis- 5 3.5 ϫ 10 sues from several donors. For MV infection, each block of tissue was inoculated with 5 mL of a 500 TCID 50 /mL viral solution, with the exception of tissue blocks from 2 patients for which the inoculum of MVwtD4 was 170 TCID 50 /mL. Culture media were sampled, fully changed, and replaced every 3 days. Matched uninfected tissue blocks were used as controls.
Flow-cytometric analysis. At day 3, 6, 9, or 12 after infection, single-cell suspensions were prepared from tissue blocks by digestion with a 1% solution of collagenase IV (Invitrogen) for 30 min, followed by a mechanical dispersion with a pestle. Dead cells were identified using the LIVE/DEAD Fixable Blue Dead Cell Stain Kit (Invitrogen).
Infections of memory and naive T cells and their correlation with the frequencies of SLAM expression were determined using the following staining: anti-CD3-Cy7-phycoerythrin (PE), anti-CD3-Cy5.5-allophycocyanin (APC), anti-CD4-Cy5.5-APC, anti-CD4-Alexa 610-PE, anti-CD8-Pacific Blue, anti-CD19-Cy7-PE, anti-CD62L-Cy7-APC, anti-CD45RA-Cy5.5-PE, anti-CD45RA-Tricolor, anti-CD45RO-Cy5-PE (all from Invitrogen-Caltag), anti-CD45RO-APC, and anti-CD150-PE (both from BD Pharmingen). Cells were permeabilized by Fix&Perm (Invitrogen-Caltag), and MV infection was determined with a fluorescein isothiocyanate-labeled monoclonal antibody to MV nucleocapsid (N) protein (Chemicon International).
Infection of NK cells, B cells, macrophages, and DCs was assessed using the following staining: anti-CD3-Cy7-PE, anti-CD3-CY5.5-APC, anti-CD16-Texas Red-PE, anti-CD56-Texas Red-PE, anti-CD14-Cy5.5-PE, anti-CD14-Alexa 750-APC, anti-CD19-Alexa 750-APC, anti-CD19-Cy7-PE, anti-HLA- DR-Cy5.5-PE, anti-CD13-Tricolor (all from Caltag), anti-CD150-PE, anti-CD20-Cy7-PE, anti-CD11c-APC, anti-CD123-PE (all from BD Pharmingen), and the anti-MV-N protein as described above. To estimate cell depletion, we compared the infected tissue with the control. Caltag counting beads were used to estimate cell numbers. Results were normalized by tissue weight.
Statistical analysis. Both the levels of viral infection and the proportions of cells in various leukocyte subsets varied from donor to donor [21, 37] . For each experiment, we compared infected and control tissues obtained from an individual donor in replicates of 54 tissue blocks for each data point. To analyze cell depletion, we normalized the data as the percentage of controls. Statistical analysis consisted in the calculation of mean, SD, SE, and P values using Student's t test. The significance level was set as , and actual P values are indicated P р .05 for certain series of experiments.
RESULTS
We documented receptor usage of MVvac and the 3 wild-type strains (MVwtICB, MVwtD4, and MVwtD8) selected for the study using cells expressing different receptors. Figure 1 3.5 ϫ 10 1400) of MVvac, MVwtD4, MVwtD8, or MVwtICB. These experiments were repeated with tissues from n donors, and n is reported in the table and figure describing each experiment. To ensure the consistency of inocula, viruses were expanded and titered on Vero/hSLAM cells expressing both MV receptors, SLAM and CD46 [24] .
As illustrated in figure 2 , using flow cytometry, we analyzed 5 cell populations: CD3 + (T lymphocytes), CD19 + (B lymphocytes), CD14 + (macrophages), CD16 + CD56 + (NK cells), and, as the fifth category, all other cells (including DCs). A pilot time-course analysis indicated that virus infection peaked at day 9, and titration of released virus indicated that 800-4000 infectious particles/mL accumulated in the 4 mL of medium bathing 9 tissue blocks infected with vaccine or wild-type viruses over the course of 1-, 2-, and 3-day periods (days 8-9, 7-9, or 6-9; data not shown). Thus, in this culture system, as we reported elsewhere [22] , viable viral particles are produced, although modestly. Virus titers do not increase linearly with time, which suggests limited stability. Nevertheless, up to 50% of B lymphocytes and 5%-15% of other lymphoid cell populations were infected at day 9 (see below), documenting significant replication of the inoculum that was washed away and diluted at each medium change (initial MOI, 1:1400 cells). Even in cell monolayers, 190% of infectious MV remains cell associated [38, 39] . Slight changes in the relative amounts of infection of different cell populations sometimes occurred during the 9-day incubation period, but no consistent shifts in the relative infection of these cell populations was noticed over time (data not shown). We focused our study on the peak infection levels. Results are illustrated in figure 2 We also assessed the cytotoxicity of MV in tonsillar tissue. On average, 160% of cells survived in infected blocks, compared with uninfected tissue blocks. The relative numbers of different cell types remaining on day 9 after MV infection are shown by the widths of the boxes in figure 2. These data indicate that B lymphocytes are preferentially depleted, in accordance with their higher infection levels. On average, their percentages Differential infection of memory and naive T lymphocytes. Because inefficient proliferation of human T lymphocytes after contagion is a hallmark of MV-induced immunosuppression, which can be elicited in vitro by a small number of MV-infected cells [40] , the analysis of infection efficiency in these cells is of particular interest. Moderate to low infection levels were monitored in CD3 + T lymphocytes, but, remarkably, the vaccine strain infected these cells somewhat more efficiently than did the wild-type viruses ( figure 2, light figure 3 we document data from 2 donors in whom infection was particularly high or low. In both cases, the ratios of memory:naive cells infected with the vaccine strain were close to 1, and those of cells infected with wild-type strains were close to 5. In donor A, who had low infection, MVvac infected ∼1.5 times more memory than naive cells (figure 3A; 8.3% vs. 5.4% [compare left panels]). In donor B, who had more-efficient infection, the ratio of MVvac-infected memory: naive cells was ∼0.7 ( figure 3B; 16 Preferential infection and depletion of SLAM-expressing cells. We assessed the extent of the correlation between SLAM expression and MV infection by measuring SLAM expression frequencies in different cell populations in tonsillar tissue blocks. Figure 4 shows that the cell types most efficiently infected by MV are those that most frequently express SLAM: 26% of B lymphocytes, compared with only 6% of macrophages and 4% of NK cells expressed detectable SLAM levels. Among T lymphocytes, only 2.4% of naive cells expressed SLAM, whereas ∼19% of memory cells did so. In B and T memory lymphocytes, variability of the frequencies of SLAM expression between tissue blocks from different donors was high, which probably reflects different cellular activation levels.
To assess whether SLAM expression correlates with preferential depletion, we compared cell survival in infected and matched uninfected tissue blocks. Figure 5 presents the relative numbers of cells that survived (mean, median, and SE). Infections with the vaccine or the wild-type MV strains depleted ∼1 in 3 tonsil cells: 58%-84% of cells remained alive in infected blocks, compared with uninfected blocks ( figure 5A, gray  boxes) . By contrast, depletion of SLAM-expressing cells was more pronounced, and only 23%-35% of these cells survived ( figure 5A, white boxes) . The differences in depletion between the total and the SLAM-expressing cells were statistically significant in MVvac ( ), MVwtD4 ( ), and MVwtD8 P ! .01 P ! .01 ( ). The differences were not significant in MVwtICB P p .02 (
), probably because we tested fewer donors ( ) P p .07 n p 4 in this case.
Preferential depletion of SLAM-expressing cells was most evident in T lymphocytes: 13%-26% of surviving CD3 + CD150 + cells were counted (figure 5B, white boxes), compared with 56%-79% of surviving total CD3 + cells ( figure 5B, gray boxes) . By contrast, depletion of SLAM-expressing B cells was less pronounced, 20%-33% of surviving CD19 + CD150
+ cells ( figure  5D, white boxes) , even though the depletion of total B lym- phocytes was slightly more pronounced than that of total T lymphocytes (47%-69% of surviving total CD19 + cells; figure  5C , gray boxes). Thus, SLAM-expressing T cells are more prone to succumb to MV infection than are SLAM-expressing B cells.
DISCUSSION
Human tonsillar explants as a model for MV infection in lymphoid tissue. We show here that, in human tonsillar tissue, wild-type and vaccine MV replicate robustly, infecting up to 50% of B lymphocytes and 5%-15% of other lymphoid cell populations. Infection results in moderate cell depletion. Predominant B cell infection was documented here in tonsils ex vivo and elsewhere in lymph nodes of macaques on day 7 after inoculation [6] .
Infection of tonsillar tissues ex vivo by MV contrasts with HIV-1 infection in this system [21] ; HIV-1 infects and depletes CD4 + T cells almost exclusively. However, the numbers of infected cells at any time point are lower than in the case of MV. Nevertheless, in the case of HIV-1 variants entering cells through the ubiquitously expressed CXCR4 protein, 190% of CD4 + T cells are depleted. MV depletes 74%-87% SLAM + T cells and 67%-80% SLAM + B cells. For both viruses, ex vivo infection of human tonsillar tissue reflects the respective hallmarks of in vivo infection.
Our data also indicate that the frequencies of SLAM expression in different types of tonsillar lymphoid cells approximately reflect those monitored on the corresponding cell populations circulating in peripheral blood or residing in other lymphoid organs [30] . Thus, tonsillar tissues can be used to identify the cell types supporting MV spread and to gain insights into mechanisms of tissue pathogenesis, even if the fraction of activated cells available in human tonsils surgically removed during routine therapeutic tonsillectomy may exceed that in resting human tissue.
Mechanisms of immunosuppression and vaccine attenuation. The efficiency of infection of different cell populations by the vaccine strain was significantly lower than that of wild-type strains, with one exception: the vaccine strain replicated more efficiently than wild-type strains in naive T lymphocytes. The availability of CD46, the vaccine strain receptor [31, 32] on these cells, probably accounts for the more efficient cell entry. The less-efficient vaccine strain infection of other cell types, such as memory T cells and macrophages, that also express CD46 is puzzling.
We think that, in these cells, vaccine strain infection is very inefficient or disallowed after entry through CD46. Entry of any MV strain through SLAM, a signaling protein, may prime the host cell to support viral replication, whereas entry through CD46 may not. The availability of reverse-genetics systems for the vaccine and a wild-type strain [25, 35] will allow the assessment of whether the capacity to replicate in naive T cells does or does not segregate with the attachment protein, in particular with the residues that interact with CD46 [41] . In this system, the alternative hypothesis that these strains differ in their ability to interfere with host innate immunity can also be addressed. It is also possible that subcutaneous inoculation of the vaccine may account in part for attenuation. This hypothesis can be tested in mice expressing both MV receptors with human-like tissue specificity [8, 42] .
MV-induced immune-suppression is a multifactorial process: the number of circulating T lymphocytes is reduced during acute measles, and the CD4:CD8 ratios are often altered [43, 44] . MV also infects tissue macrophages and circulating monocytes, causing their apoptosis [45, 46] . Moreover, DC infection, even if inefficient, may be a factor in immune suppression [4] . Consistent with multiple immune suppression mechanisms, all the immune cells examined in the present study-including lymphocytes, macrophages, NK cells, and DCs-were infected. Wild-type strains infected tissue macrophages responsible for innate response, memory T lymphocytes, and B lymphocytes involved in adaptive immune responses more efficiently than did the vaccine strain. Thus, more-efficient infection of several types of immune cells by wild-type MV strains may contribute to a more-pronounced immune suppression.
SLAM-expressing T lymphocytes succumbed to MV infection more readily than did SLAM-expressing B lymphocytes, which suggests that MV adopts a multiplication strategy compatible with the survival of B lymphocytes residing in lymphatic organs. In animals inoculated with another morbillivirus, canine distemper, primary and secondary lymphoid organs are rapidly infected, initially with little tissue destruction [11] . Thus, the results of MV ex vivo and canine distemper in vivo studies are consistent with a common morbillivirus replication strategy, which was based initially on extensive but moderately cytopathic infection of SLAM-expressing cells, in particular B lymphocytes. Receptor "detargeting" through gain of CD46-dependent entry by the vaccine strain, by altering the viral adaptation to this host cell niche, may elicit an earlier and more-efficient immune response. Combined with suboptimal control of the host innate response, it may result in attenuation.
